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Background:  Modified body mass index (mBMI), (BMI x serum albumin) predicts clinical outcomes after liver-transplant for transthyretin-
related amyloidosis (ATTR). We sought to evaluate the utility of mBMI to predict outcomes in patients with cardiac amyloidosis undergoing 
orthotopic heart transplantation (OHT).
methods:  Patients (n=145) waitlisted for OHT with AL or ATTR cardiac amyloidosis at ten institutions with available BMI at the time of 
transplant evaluation were included. Data obtained via chart review was entered into the encrypted online database, Research Electronic 
Data Capture (REDCap). mBMI was stratified by the mean value; clinical outcomes were stratified by type of amyloid. Survival by mBMI 
was compared using the Kaplan Meier method and multivariate Cox-proportional hazards models.
results:  Low mBMI patients had lower left ventricular end diastolic diameter (P=0.03), and higher natriuretic peptides (P=0.01), but not 
higher waitlist mortality (63.8% vs. 51.3%; P=0.2), without major differences in demographic and hemodynamic parameters. mBMI was not 
associated with survival in both AL and ATTR amyloid (log-rank P>0.5) (median follow-up 3.2 years). After adjusting for baseline factors and 
type of amyloidosis, mBMI did not predict waitlist mortality (P>0.5).
conclusion:  Distinct from patients with ATTR amyloid undergoing liver transplantation, mBMI was not predictive of adverse outcomes in 
cardiac amyloidosis undergoing OHT.
Table 1: Demographic, hemodynamic, & echocardiographic characteristics stratified by mBMI
mBMI 
< Mean
mBMI 
> mean p-value
Age (years) 56.0±7.9 55.2±10.8 0.6
Weight (kg) 72.6±12.7 87.0±18.3 <0.001
Gender, male 41 (59.4%) 42 (55.3%) 0.3
Race, white 53 (76.8%) 50 (65.7%) 0.2
BMI (kg/m2) 23.9±3.0 29.3±5.4 <0.001
Albumin (g/L) 3.311 3.96 <0.001
AL (vs. ATTR) amyloidosis 57 (82.6%) 54(71.1%) 0.2
NYHA III or IV 55 (79.7%) 67 (88.2%) 0.2
Mean Arterial Pressure (mmHg) 77.0±13.3 77.7±12.5 0.7
Cardiac Index (L/min/m2) 1.8±0.4 1.9±0.5 0.6
Right Atrial Pressure (mmHg) 13.3±6.0 13.6±6.7 0.7
Pulmonary artery systolic pressure (mmHg) 41.6±12.3 41.9±11.1 0.9
Pulmonary capillary wedge pressure (mmHg) 21.1±6.7 20.4±6.7 0.6
Left ventricle end diastolic diameter (cm) 4.0±0.7 4.2±0.6 0.03
Posterior wall thickness (cm) 1.6±0.3 1.6±0.4 0.2
Septal wall thickness (cm) 1.6±0.4 1.6±0.4 0.7
Left ventricle ejection fraction (%) 37.6±13,1 39.8±13.3 0.3
NT-proBNP (pg/mL) 15763.6±15941.7 5793.9±3960.3 0.01
BNP (pg/mL) 3207.4±5108.8 1073.3±1134.9 0.01
Mechanical circulatory support 17 (24.6%) 17 (22.4%) 0.9
